You are here

Electrophysiology & Arrhythmia


For nearly 6,000 patients with heart failure and chronic kidney disease (CKD), the use of an implantable cardioverter defibrillator (ICD) showed no mortality benefit but a higher risk of subsequent hospitalizations after covariate adjustment, researchers reported in JAMA Internal Medicine.

Catheter ablation was associated with significantly fewer deaths and hospitalizations for worsening heart failure than medical therapy in a randomized trial of patients with atrial fibrillation (AFib) and heart failure.

A pair of researchers at Utah State University are aiming to revolutionize the world of digital monitoring with a new technology that can measure a person’s heartbeat using nothing more than a video camera and specialized software, the university announced Monday.

Atrial fibrillation (AFib) patients face higher odds for short-term cancer diagnoses but, depending on how long they've had AFib, the could face lower odds for cancer in the long run, a January study states.

Nearly half of all out-of-hospital cardiac arrest (OHCA) survivors struggle to rejoin the workforce and participate in society post-heart attack, a study published in Circulation: Cardiovascular Quality and Outcomes suggests.


Recent Headlines

Baseline Q wave associated with increased risk of death
Data acquired in over 4,500 STEMI patients treated with primary PCI, provide novel and compelling evidence about the importance of a Q-wave on the baseline ECG as an independent prognostic marker of clinical outcome, according to a study in the April 28 issue of the Journal of the American College of Cardiology.
FDA sends warning letter to St. Jude a-fib manufacturing facility
St. Jude Medical received a warning letter dated April 17 from the FDA related to its atrial fibrillation (AF) division manufacturing facility in Minnetonka, Minn., which makes Safire ablation catheters.
St. Jude Q1 earnings propelled by strong cardiovascular sales St. Jude Medical has reported a 16 percent uptick in net earnings, to $201 million from $177 million, for its fiscal 2009 first quarter, which ended April 4.
JAMA: Patients have better outcomes when electrophysiologists implant ICDs Patients whose implantable cardioverter-defibrillators (ICDs) are implanted by non-electrophysiologists are at increased risk of complications and are less likely to receive a specific type of ICD when clinically indicated, according to a study published in the April 22/29 issue of the Journal of the American Medical Association.
Oracle steps in to buy Sun for $7.4B
Oracle has crafted an agreement to buy server vendor Sun Microsystems for approximately $7.4 billion, or $5.6 billion net of Sun's cash and debt.
Remotely Navigating the Heart with Water-Cooled Catheters The FDA in February approved the NaviStar ThermoCool Catheter (Biosense Webster) to treat atrial fibrillation (AF), the first ablation catheter in the U.S. to be approved to treat AF.
Cardiome could get $600M from Merck in a-fib drug deal Merck and Cardiome have formed a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation.
IBM withdraws $7B bid for Sun Microsystems
IBM has withdrawn its $7 billion bid for Sun Microsystems, after Sun's board of directors rejected the offer as being too low.
Atritech nets $30M to complete FDA review of Watchman device Atritech, a clinical-stage medical device company, has completed a $30 million round of financing, led by Thomas, McNerney & Partners along with an investment from Split Rock Partners and insider investments from Prism Ventures, Tullis-Dickerson and Vector Group.
Implantable device may replace drugs in AF patients with stroke risk ORLANDO, Fla.A device percutaneously implanted in the left atrial appendage may replace anti-thrombotic drugs for stroke prevention in patients with nonvalvular atrial fibrillation (AF), according to research presented during the i2 Summit at the American College of Cardiology (ACC) 58th annual scientific sessions.